Loading…
Tuesday, March 14
 

7:30am PDT

Registration and Networking Breakfast
Tuesday March 14, 2023 7:30am - 8:15am PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Networking

8:15am PDT

Chairperson’s Opening Remarks
Speakers
avatar for Michael Myers

Michael Myers

Associate Vice President, Lilly Research Labs Due Diligence, Eli Lilly
Dr. Mike Myers has worked >30 years in pharma and has spent his career contributing to the discovery and development of new drugs. He is an inventor on 35 patents and has led teams in the pursuit of innovative treatments for cancer, CNS, infectious and cardiovascular disease. Mike... Read More →

Tuesday March 14, 2023 8:15am - 8:30am PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Business Development

8:30am PDT

Interactive Opening Roundtable Discussion
This conversational style group discussion will serve as an opportunity for attendees to interact with and learn from their colleagues and benchmark their practices in accordance with other organizations and industry standards.
Tuesday March 14, 2023 8:30am - 9:00am PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Networking

9:00am PDT

Panel: The Big Picture: Understanding Big Pharma’s Deal Drivers, Current Priorities and Processes
  • Identifying current priorities for big pharma including leading therapeutics areas for development and types of deals (i.e. – license vs. M&A)
  • How to identify and interact with the key decision-makers, including board members, to get buy-in for the deal and streamline the deal-making process
  • Understanding how pharma is assessing risk in the current economic climate
  • Discussing the factors taken into consideration when pharma is making strategic choices about which deals to move forward with
Moderators
avatar for Chris DeRespino

Chris DeRespino

Chief Business Officer, 3T Biosciences
Chris DeRespino serves as chief business officer at 3T Biosciences, an industry leader in TCR targeting and therapeutics discovery. In this role, Mr. DeRespino is responsible for leading business development and corporate strategy. Previously, Mr. DeRespino was CBO and acting chief... Read More →

Speakers
avatar for Niels Emmerich, Ph.D.

Niels Emmerich, Ph.D.

Vice President, Global Head Search & Evaluation, AbbVie, Inc.
After joining Abbott in 2011, Niels has held several positions with Abbott and, since its inception in 2013, AbbVie, currently serving in the Corporate Strategy Office as Vice President, Global Head of Search & Evaluation. Transactions that his group and Niels were involved in include... Read More →
avatar for Deepa Talpade

Deepa Talpade

Vice President, Head BD&L and Alliance Mgmt., Oncology, Bayer Pharmaceuticals
Deepa Talpade has over 20 years of experience in the Pharmaceutical Industry working in all phases of Business Development and across therapeutic areas combining extensive BD&L experience, business insight, strategic thinking, industry partnering and leadership experience in leading... Read More →
avatar for Siobhan Pomeroy

Siobhan Pomeroy

Vice President, Corporate Development, Gilead Sciences
avatar for Grace Han McMahon

Grace Han McMahon

AVP and Head, Pacific BD&L, Merck
Grace Han McMahon leads Merck’s Pacific Business Development & Licensing group in South San Francisco and Asia.  Her team focuses on preclinical through early clinical therapeutic opportunities (pre-proof of concept in patients) across multiple therapeutic areas and various modalities... Read More →

Tuesday March 14, 2023 9:00am - 9:45am PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Business Development

9:45am PDT

Panel: Strategies for Survival: Looking at Alternative Deal Constructs and Creative Financing to Endure Market Instability
  • How do you decide what the “right” deal structure is for the collaboration?
  • Using non-diluted funding, other non-equity financing or option-based deals to stay afloat
  • Building flexibility into the deal structure to account for uncertainty
  • Deciding whether to go the M&A route vs. alliances or product acquisition
  • Going beyond the conventional: Examples of innovative deal structures: joint ventures, subsidiary programs, royalty financing and more
  • Tips for structuring a deal that is win-win for both sides

Moderators
avatar for Mark Stead

Mark Stead

Senior Business Development Director, Exelixis, Inc.
Mark Stead, Ph.D. is Senior Business Development Director at Exelixis, Inc. In this role, he is responsible for the negotiation of partnerships and strategic transactions on behalf of Exelixis as it strives to accelerate the discovery, development and commercialization of new medicines... Read More →

Speakers
avatar for Michael Bologna

Michael Bologna

Partner, NovaQuest Capital Management
Mike Bologna, Partner at NovaQuest Capital Management, has over 20 years of experience in the biomedical industry across pharmaceuticals and health care investing. He is responsible for sourcing, negotiating, due diligence, structuring of investment opportunities, and post-close investment... Read More →
avatar for David Brower

David Brower

Chief Business Officer, Accent Therapeutics
David Brower joined Accent Therapeutics in September 2018 and serves as Chief Business Officer. David has held a number of life science business development, strategy, and investing roles prior to joining Accent. Most recently, David led the business development function for Blueprint... Read More →
avatar for Ahmed Mousa

Ahmed Mousa

Senior Vice President, Chief Business Officer and General Counsel, Pieris Pharmaceuticals
Ahmed is the Senior Vice President, Corporate Operations and General Counsel of Pieris Pharmaceuticals where he acts as site head for the company's Boston office, oversees the centralized project leadership and quality assurance functions, and leads Pieris’ intellectual property... Read More →
avatar for Ramlah Nehring, PhD

Ramlah Nehring, PhD

Head of Strategy and Transactions, Roche Diagnostics
Ramlah Nehring, Ph.D. is the Head of Strategy and Transactions at Roche Diagnostics, she is based in San Diego, California and leads a global team across APAC, North America and Europe. Her team leads deals for Roche Diagnostics across the spectrum of partnerships, licensing, and... Read More →

Tuesday March 14, 2023 9:45am - 10:30am PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Business Development

10:30am PDT

Networking Break
Tuesday March 14, 2023 10:30am - 11:00am PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Networking

11:00am PDT

The Innovation Constellation – Re-Thinking the Traditional Large Cap Pharma BD Model and Ecosystem
  • Outline industry-wide challenges and macroeconomic headwinds that are driving change in pharma’s current inorganic growth strategies
  • Discuss recent research evaluating how innovation was sourced, and the resulting historical success across mid-to-large cap pharma
  • Explore how companies may re-balance their investment mix to optimize capital efficacy and long-term return
Speakers
avatar for Cody Powers

Cody Powers

Principal, ZS Associates
Cody is a principal in ZS’s New York office, where he leads the portfolio and business development practice—helping clients address both “where to play” strategy and inorganic growth challenges.  Cody has over 13 years of experience in healthcare and life sciences consulting... Read More →

Tuesday March 14, 2023 11:00am - 11:30am PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Business Development

11:30am PDT

Panel: Search and Evaluation Strategies for Choosing the Right Business Partner to Advance Innovation
  • Analyzing the company’s portfolio and underlying business goals and identifying gaps for growth
  • Evaluating different operating models for search and evaluation
  • Factors to take into consideration when selecting a partner
  • Creating alignment between partners to ensure a successful collaboration

Moderators
avatar for Craig Farrell

Craig Farrell

GTM Director, Life Sciences, AlphaSense
Craig Farrell is a member of the Go-To-Market Strategy team at AlphaSense with responsibilities for both the Life Science vertical, as well as the enterprise search offering termed Internal Insights. He began his career in a Molecular Cytology research lab at Memorial Sloan Kettering... Read More →

Speakers
avatar for Ravi Kiron, PhD, MBA

Ravi Kiron, PhD, MBA

Head, BioPharma External Innovation, EMD Serono, Inc.
Dr. Ravi Kiron based in California, USA is an experienced pharma/biotech executive with decades of experience in discovery R&D through late-stage clinical development, intellectual property and regulatory, technology & business development, M&A, strategy and product commercialization... Read More →
avatar for Dominic McDonald, MBA

Dominic McDonald, MBA

Senior Director, Search & Evaluation, Oncology R&D Business Development, AstraZeneca
Dominic is currently a Senior Director, Search & Evaluation within AstraZeneca’s Oncology R&D Business Development group. Selected transactions that Dominic has completed include the licensing of TNB-486 (CD19/CD3 BiSpecific) from TeneoBio as well as the acquisition of Neogene Therapeutics... Read More →
avatar for Garrett Rhyasen, PhD

Garrett Rhyasen, PhD

Vice President, Head of Search, Evaluation, and Transactions, GSK
Garrett Rhyasen is Vice President of Oncology Search & Evaluation at GSK, where he leads a team of BD professionals responsible for sourcing, technical evaluation, and business case delivery of partnering opportunities.Prior to GSK, Garrett was Executive Director of and Global Head... Read More →
avatar for Nikhil Mutyal, PhD

Nikhil Mutyal, PhD

Executive Director, Business Development and Licensing, Merck
Nikhil Mutyal, Ph.D. is Executive Director, Business Development and Licensing in Pacific Hub for Merck and Co (known as MSD outside of United States) based in San Francisco. Dr. Mutyal leads BD&L efforts for Oncology, Neuroscience and Cardiometabolic diseases for therapeutic opportunities... Read More →

Tuesday March 14, 2023 11:30am - 12:15pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Business Development

12:15pm PDT

Networking Lunch
Tuesday March 14, 2023 12:15pm - 1:30pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Networking

1:30pm PDT

Grow Your Drug Hunter Acumen
As an active partner in the Pharma/Biotech innovation ecosystem, you cannot help but learn the art of being a Drug Hunter. If unfamiliar with this concept, a Drug Hunter is a Leader that works as a part of a multi-disciplinary professional team working to discover and develop new drugs. Your job as a BD&L Professional is to negotiate access to innovation (selling or buying/partnering) and of course your job is easier if you yourself are fluent in appreciating the end-in-mind aspect of the innovation being discussed. This provocative topic is meant to open a dialogue within our community on the following questions:
  • What makes for a great drug hunter?
  • How fast do you grow YOUR new talent?
  • What transferable skills in particular make for being an effective BD&L partner?
  • What special knowledge puts a BD&L professional in a position to lead your organization in deal-making?
Speakers
avatar for Michael Myers

Michael Myers

Associate Vice President, Lilly Research Labs Due Diligence, Eli Lilly
Dr. Mike Myers has worked >30 years in pharma and has spent his career contributing to the discovery and development of new drugs. He is an inventor on 35 patents and has led teams in the pursuit of innovative treatments for cancer, CNS, infectious and cardiovascular disease. Mike... Read More →

Tuesday March 14, 2023 1:30pm - 2:00pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Business Development

2:00pm PDT

Speed Business Networking Break
Grab your business cards and connect with other attendees during this structured networking break. Attendees will have the opportunity to meet with multiple professionals one-on-one to exchange information and discuss partnering opportunities and interests.
Tuesday March 14, 2023 2:00pm - 3:15pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Business Development

3:15pm PDT

Networking Break
Tuesday March 14, 2023 3:15pm - 3:30pm PDT

3:30pm PDT

Case Study: Harbour BioMed-- Technology Platform Value Maximization
  • A look at the history of our company as a technology platform
  • Examining the value proposition, creation, and realization (PCR) at Harbour
  • Value proposition: early validation via several technology licenses with big pharma
  • Value creation: how we build an asset portfolio to further showcase our platform
  • Value realization: creating asset licenses with big pharma to realize the value of these assets
  • Value expansion: platform, plus discovery platform established as an independent entity
Speakers
avatar for Weihao Xu

Weihao Xu

Chief Financial Officer & Chief Business Officer, Harbour BioMed
Mr. Weihao Xu, is Chief Financial Officer and Chief Business Officer at Harbour BioMed, a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases... Read More →

Tuesday March 14, 2023 3:30pm - 4:00pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Business Development

4:00pm PDT

Panel: Advance your Assets: Strategies for Negotiating and Evaluating Platform Deals
  • Identify trends, new modalities and enabling technologies including drug discovery platforms, gene editing, AI and digital health
  • Understanding the differences between platform vs. product deals including valuation and deal structures
  • Defining success for these deals and creating collaborations that will benefit both parties
Moderators
avatar for Ekaterine (Eka) Kortkhonjia

Ekaterine (Eka) Kortkhonjia

Sr. Director, Early Innovation Partnering, Johnson & Johnson
Eka is a Senior Director of Early Innovation Partnering at Johnson and Johnson. In this role Eka is responsible for identification, diligence and strategic transactions for data science opportunities across therapeutic areas from discovery through commercial execution. Eka joined... Read More →

Speakers
avatar for Anne Stevens

Anne Stevens

VP of Business Development, AbCellera
Ms. Stevens is currently the Head of Business Partnering at AbCellera Biologics Inc., as well as a Director for Aequus Pharmaceuticals and the LifesciencesBC organization. Ms Stevens was previously the Chief Operating Officer of Aequus Pharmaceuticals, a specialty pharmaceutical company... Read More →
avatar for Michelle Chen

Michelle Chen

Chief Business Officer, Insilico Medicine
Michelle Chen is the Chief Business Officer of Insilico Medicine, a leader in the AI-powered drug discovery and development company.She is responsible for company’s strategies, business and corporate development, revenue growth and US operations. As a biotech executive, Michelle... Read More →
avatar for Scott Saywell

Scott Saywell

Chief Business Officer, Herophilus
Scott Saywell is the Chief Business Officer at Herophilus, a San Francisco-based neurotherapeutics company focused on curing brain diseases with its proprietary technology platform based on in vitro human tissue models.  Scott has over twenty-five years of experience in the biotech... Read More →
avatar for Jeff Landau

Jeff Landau

Chief Business Officer, CytomX Therapeutics
Jeff Landau is currently SVP, Chief Business Officer and Head of Strategy at CytomX Therapeutics (www.cytomx.com) where he leads BD&L, Corporate Strategy, Alliance and Program Management and New Product Planning and has recently closed platform deals with Regeneron and Moderna. Mr. Landau has over 20 years of biopharmaceutical experience in corporate development, corporate strategy, sales and new... Read More →

Tuesday March 14, 2023 4:00pm - 4:45pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Business Development

4:45pm PDT

Panel: The VC Perspective: Deal Drivers, Financing Options and Trends for 2023
  • Understanding the different approaches taken by VCs for their financing models
  • Looking at the biggest opportunities for growth
  • What metrics and criteria are VCs looking at during their diligence process and what drives their decision making especially in the current economic climate?
  • Vetting your VCs: Factors to take into consideration when deciding what route to take
Moderators
avatar for Laura Berner

Laura Berner

Chief Operating Officer, TRexBio
Laura Berner brings extensive experience in corporate development, corporate and strategic transactions, investor relations, strategy and operations to her role as Chief Operating Officer of TRexBio. Most recently, she was VP, Head of Business Development & Investor Relations at Myovant... Read More →

Speakers
avatar for Seth Lieblich

Seth Lieblich

Principal, 8VC
Seth joined 8VC from Amgen’s Business Development technology group, where he was responsible for search & evaluation and transactions for platform technologies across a number of therapeutic and functional areas. Seth was also responsible for strategic academic partnerships across... Read More →
avatar for Mariana Mihalusova, PhD, MBA

Mariana Mihalusova, PhD, MBA

Vice President, Venrock
Mariana Mihalusova focuses on biotech and pharmaceutical investments, and is currently a Board Observer at Mythic Therapeutics and Ocelot Bio. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to... Read More →
avatar for Christopher Mauney

Christopher Mauney

Senior Associate, NovaQuest Capital Management
Chris Mauney, Senior Associate at NovaQuest Capital Management, has experience advancing a range of drug development and regulatory programs across diverse indications and therapeutic modalities. He is responsible for due diligence, structuring of investment opportunities, and post-close... Read More →

Tuesday March 14, 2023 4:45pm - 5:45pm PDT
Hyatt Centric Fisherman's Wharf San Francisco

5:45pm PDT

Chairperson's Closing Remarks
Speakers
avatar for Michael Myers

Michael Myers

Associate Vice President, Lilly Research Labs Due Diligence, Eli Lilly
Dr. Mike Myers has worked >30 years in pharma and has spent his career contributing to the discovery and development of new drugs. He is an inventor on 35 patents and has led teams in the pursuit of innovative treatments for cancer, CNS, infectious and cardiovascular disease. Mike... Read More →

Tuesday March 14, 2023 5:45pm - 6:00pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Business Development

6:00pm PDT

Networking Cocktail Reception
Tuesday March 14, 2023 6:00pm - 6:45pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Networking
 
Wednesday, March 15
 

8:30am PDT

Networking Breakfast
Wednesday March 15, 2023 8:30am - 9:15am PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Networking

9:15am PDT

Chairperson’s Opening Remarks
Speakers
avatar for Michael Myers

Michael Myers

Associate Vice President, Lilly Research Labs Due Diligence, Eli Lilly
Dr. Mike Myers has worked >30 years in pharma and has spent his career contributing to the discovery and development of new drugs. He is an inventor on 35 patents and has led teams in the pursuit of innovative treatments for cancer, CNS, infectious and cardiovascular disease. Mike... Read More →

Wednesday March 15, 2023 9:15am - 9:30am PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Due Diligence

9:30am PDT

Interactive Opening Roundtable Discussion
This conversational style group discussion will serve as an opportunity for attendees to interact with and learn from their colleagues and benchmark their practices in accordance with other organizations and industry standards.
Wednesday March 15, 2023 9:30am - 10:15am PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Due Diligence

10:15am PDT

Panel: Making your Company an Attractive Target: Maximizing the Value of your Assets and Preparing for a Diligence Review
  • Understanding the current trends and priorities of pharma and looking at what data is needed to withstand scrutiny
  • How should a seller position their assets with confidence during the initial conversation and as the diligence review advances
  • Best practices for pitching your assets
  • Identify what documentation the buyer needs and preparing the relevant documentation for review
  • Building trust through transparency
Moderators
avatar for Elina Lavit

Elina Lavit

Vice President of Business Development, OncoNano Medicine
Elina Lavit is VP of Business Development at OncoNano Medicine.Elina brings over 19 years of experience in leadership roles in organizations ranging from start-ups to Fortune 100 corporations in various therapeutic areas, including oncology, surgery, cardiology, and neurology.Prior... Read More →

Speakers
avatar for Reza Afkhami

Reza Afkhami

SVP, Corporate Development and Strategy, Global Blood Therapeutics
avatar for Samuel Zhang, PhD, MBA

Samuel Zhang, PhD, MBA

Chief Business Officer, Gracell Biotechnologies
avatar for Neela Patel

Neela Patel

CBO, Bonum Therapeutics
Dr. Neela Patel is a scientist and business development executive with more than 25 years of leadership experience in drug discovery & development, project & portfolio management, and pipeline development. She currently serves as Chief Business Officer at Bonum Therapeutics. Previously... Read More →

Wednesday March 15, 2023 10:15am - 11:00am PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Due Diligence

11:00am PDT

Networking Break
Wednesday March 15, 2023 11:00am - 11:30am PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Networking

11:30am PDT

CMC: Optimize & Protect the Value of Your Asset
  • As a rule, good even great CMC package will not increase the value of an asset but a poor package can rapidly erode value
  • The key aspects of any great CMC package
    • DS Availability
    • Well documented development history and manufacturing batch records
    • Using reputable CMO’s / CRO’s
    • Analytical methods that are phase appropriate and aligned with current regulatory guidance
    • Well thought out plan for delivery of the molecule throughout the development lifecycle
    • Asking the right questions of regulatory bodies and understanding expectations
  • Invest in Quality systems and personnel
    • Having DS and DP that is not usable destroys value

Speakers
avatar for James M. Koers

James M. Koers

Sr. Director: CMC and Clinical Capabilities Business Development, Eli Lilly and Company
Jim Koers is currently the Sr. Director for CMC Business Development at Eli Lilly and Company based in Indianapolis, IN. Jim has 20 year’s experience in the Pharma industry with roles in analytical chemistry, CMC Project management and Business Development. Prior to the past 12... Read More →

Wednesday March 15, 2023 11:30am - 12:00pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Due Diligence

12:00pm PDT

Networking Lunch
Wednesday March 15, 2023 12:00pm - 1:00pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Networking

1:00pm PDT

Panel: Conducting a Thorough and Effective IP Due Diligence Review: Uncovering the IP Issues that can Derail the Deal
  • Overview of the current status of IP law – what new areas to look out for – written description, antibodies etc.
  • Evaluating IP in platform deals
  • Identifying any ownership conflicts or infringement risks
  • Ways to address the IP problems to save the deal
  • Making a patent portfolio attractive to buyers
  • Patent term extensions and exclusivity analysis
  • Impact of the IP analysis on valuation
Moderators
avatar for Olga Zimmerman

Olga Zimmerman

Director, Intellectual Property, Caribou Biosciences
Olga is Director, Intellectual Property at Caribou Biosciences where she is responsible for all aspects of intellectual property, including patent and trademark prosecution, freedom to operate reviews and due diligence analysis. Prior to Caribou, Olga served as Senior Counsel, Intellectual... Read More →

Speakers
avatar for Forrester Liddle

Forrester Liddle

Vice President, Intellectual Property and Contracts, Jounce Therapeutics, Inc.
avatar for Lindsey Wanner, JD

Lindsey Wanner, JD

Associate General Counsel, IP Alliance and Due Diligence, Gilead Sciences
Lindsey is an IP lawyer with over 18 years of experience working in life sciences. She has deep expertise in pharmaceutical patent practice. She leads IP due diligence teams and assists in contract negotiation to support strategic transactions.
avatar for William Coppola

William Coppola

Former Vice President, Intellectual Property, Aerie Pharmaceuticals

Wednesday March 15, 2023 1:00pm - 1:45pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Due Diligence

1:45pm PDT

Successfully Navigate Antitrust Aspects of Future Transactions
  • Gain an overview of recent U.S. and global antitrust enforcement trends
  • Discuss key tactics to manage the expectations of your partners
  • Develop an efficient process to assess antitrust risks while increasing the speed of clearance reviews
Speakers
avatar for Kelly Fayne

Kelly Fayne

Partner, Latham & Watkins
Kelly Fayne is a partner in the San Francisco office of Latham & Watkins and a member of the Antitrust & Competition Practice. Ms. Fayne is a globally recognized advisor of clients in government reviews of mergers and acquisitions, antitrust compliance and counseling, and government... Read More →

Wednesday March 15, 2023 1:45pm - 2:15pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Legal

2:15pm PDT

Panel: Drafting and Negotiating Key Contract Terms to Minimize Future Risks
  • Working with the BD&L team to ensure that the terms included in the agreement can be executed
  • Tailoring the terms to the specific goals and type of the deal
  • Identifying the most complicated and problematic parts of the contract process and  best practices for proactively addressing them
  • Adapting critical contract terms based on the deal structure and to ensure the success of the alliance
Moderators
avatar for Yina Dong

Yina Dong

Deputy General Counsel, Veracyte
Yina Dong is Deputy General Counsel at Veracyte, where she manages global contracting and IP strategy. Yina started her legal career at Latham & Watkins’ life sciences technology transactions group, handling licensing and partnering transactions and advising on IP matters in M&A... Read More →

Speakers
avatar for Jeannie Karl, PhD, JD

Jeannie Karl, PhD, JD

Senior Director, Transaction Excellence Pharma Partnering, Genentech
avatar for Mark Kafka

Mark Kafka

Vice President, Intellectual Property & Transactions, Denali Therapeutics
Mark is Vice President, Intellectual Property & Transactions, at Denali Therapeutics where he leads all IP and strategic partnering matters on behalf of Denali's legal department. Prior to joining Denali, Mark was Senior Director, Associate General Counsel at Genentech and acted as... Read More →
avatar for Jeff Cohn

Jeff Cohn

Executive Director, Assistant General Counsel & Assistant Secretary, Heron Therapeutics
Jeff Cohn has more than 15 years of legal, business and life sciences experience, including in therapeutics, medical devices, diagnostics and analytics.  He currently serves as Executive Director, Assistant General Counsel & Assistant Secretary for Heron Therapeutics, Inc., where... Read More →

Wednesday March 15, 2023 2:15pm - 3:00pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Legal

3:00pm PDT

Chairperson's Closing Remarks
Wednesday March 15, 2023 3:00pm - 3:15pm PDT
Hyatt Centric Fisherman's Wharf San Francisco
  Due Diligence
 
Filter sessions
Apply filters to sessions.
Tuesday, March 14
Wednesday, March 15
  • Business Development
  • Due Diligence
  • Legal
  • Networking
    • Hyatt Centric Fisherman's Wharf San Francisco